WASHINGTON--(BUSINESS WIRE)--April 3, 2006--ZIOPHARM Oncology, Inc. (OTC BB: ZIOP - News) announced data from preclinical studies of the activity of ZIO-201 and two halogenated analogs, ZIO-202 and ZIO-203, during the American Association for Cancer Research (AACR) meeting in Washington, D.C. These data show ZIO-201 is active against cisplatin (CDDP)-resistant leukemia cells. ZIO-201 and cisplatin had similar activity in leukemia cells (P388) sensitive to cisplatin but ZIO-201 had about an eight-log cell kill greater anti-leukemia activity against cisplatin-resistant cells. The data also show that anti-cancer activities of ZIO-201, ZIO-202, and ZIO-203 are similar in human pancreas and prostate cancer xenografts and that many schedules were active. The data were presented by Robert F. Struck, Ph.D and co-authors from Southern Research Institute.
